Contract Pharma: Altasciences Acquires Sinclair Research
Altasciences Acquires Sinclair Research and Continues to Expand Preclinical Platform
Laval, Quebec, January 4, 2022 – Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest. Complementing existing locations on the East and West Coast, the new site will facilitate even greater access to Altasciences’ preclinical services across the U.S.
“This acquisition will add significant capacity and expertise to Altasciences’ existing preclinical offering,” said Steve Mason, Co-Chief Operating Officer at Altasciences. “Sinclair’s experience conducting research on a wide variety of species in a comprehensive range of drug classes will broaden our current preclinical offering and support Altasciences’ focus on providing our clients with customized solutions.”
With over 80 animal rooms, Sinclair Research is a large nonclinical CRO in the U.S.A. providing full-service IND and NDA-enabling toxicology and safety pharmacology services. Built on more than 50 years of experience, Sinclair Research provides services to support biopharmaceutical, animal health, and medical device development programs. “We are very excited to be joining the Altasciences team, and look forward to being able to offer our preclinical services to a broader market by leveraging the resources and expertise of an integrated, global CRO,” stated Guy Bouchard, Chief Executive Officer at Sinclair Research.
“With this acquisition, Altasciences is continuing to advance its strategic growth plan to provide an expanded range of services in support of our integrated early-phase drug development solutions. Sinclair Research shares our commitment to animal welfare, and we look forward to merging our talents and working together with our new team of preclinical experts in the Midwest,” added Chris Perkin, Altasciences’ Chief Executive Officer.
Fredrikson & Byron P.A. and Goodwin Procter LLP served as legal advisors to Altasciences on the transaction. Fairmount Partners acted as exclusive financial advisors to Sinclair, and Troutman Pepper acted as legal counsel.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
CONTACT:
Julie-Ann Cabana
Altasciences
514 601-9763
jcabana@altasciences.com
2021 Year in Review
|
|||||||||||||||||||||||||||||||||||||||||||
|
In 2021, you did incredible things — and we are grateful to have been part of your journey. Top Scientific Resources of 2021
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the KneeDecember 2021In this issue Complimentary industry webinars and podcasts, thought-provoking articles, industry news, and more! QUICK LINKS The Altascientist: Scientific Journal Read the latest issue: “Psychedelics and Entactogens: Challenges Associated with Schedule I Therapeutics”. Four Reasons to Choose Altasciences as Your Flow Cytometry Partner Given the highly specialized nature of flow cytometry testing and the unique set of competencies required to carry it out, choosing the right partner is key to ensuring a successful study. Psychedelics — Regulatory Environment Challenges In the past, stigmatization and criminalization have blocked psychedelics from realizing their full potential in medicine and scientific research. Now, with growing research and education, this is all changing. In this article, we explore the past, present, and future regulatory environment for Schedule I therapeutic development. Citeline Awards Names Altasciences as a Finalist for Best Sponsor-facing Technology Initiative of 2021 Altasciences was shortlisted for its proprietary database, Ask Albert. Ask Albert is behind our commitment to fueling integration and facilitating information-sharing across departments and sites, so that you only have to Tell Us Once™. Altasciences’ CDMO site in Philadelphia, PA will manufacture the world’s first FDA-approved inhaled smoking cessation therapy. This treatment uses RespiRx™, a vibrating mesh nebulizer (VMN) with a disposable cartridge that is maintenance-free, reliable, and eliminates the risk of patient misuse. Global Business Reports Interviews Altasciences’ CEO In a one-on-one interview with GBR, Chris Perkin discusses Altasciences’ place in early phase drug development, the company’s evolution, and its vision for the industry. XORTX Therapeutics Partners with Altasciences for Clinical Study on Kidney Disease Treatment The clinical study is in support of developing a treatment for autosomal dominant polycystic kidney disease (ADPKD) and for acute kidney injury associated with Coronavirus infection. CDMO Expansion Continues with Additional Facilities in Philadelphia Contract Pharma reports on the continuing expansion of Altasciences’ CDMO site, specifically the launch of a second client-dedicated building project. Altasciences Contributes to the Clinical Development of Bisoprolol/Ramipril Fixed-Dose Combination Read about the study findings of three studies conducted at Altasciences in this article published in Clinical and Translational Science. Up Close and Personal with… Dr. Denise Milovan Meet Altasciences’ Scientific Manager, Biostatistics, Data Services, at Altasciences. Moving Your Drug Forward to Preclinical Trials Discover key considerations when planning to transition from drug discovery to preclinical trials. Read about how, after years of stagnation, this field of research is being revitalized by the investigation of their potential benefit of mainstream psychiatric applications. BEFORE YOU GO:
Are You Looking for Help with Scientific Publications?
Scientific Publication Writing — Let Us Help!Altasciences’ scientific experts can provide you with strategic guidance and quality writing for your next scientific publication. Our solution includes writing for a wide range of therapeutic areas, for your preclinical to clinical research — as part of a full‑service program completed at our facilities or as a stand-alone offering.
Have 5 minutes? You may be interested in:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond. FDA and EMA Prefer Terminal Sterilization Over Aseptic Manufacturing ― Find Out Why
Advantages of Terminal Sterilization Over Aseptic ManufacturingRegulatory agencies such as the FDA and EMA generally prefer terminal sterilization over aseptic manufacturing, as it provides a high level of sterility assurance. It is also less complex, less costly, more easily reproducible than aseptic manufacturing, and offers time savings to pharmaceutical companies.
Read to learn how terminal sterilization can benefit your drug product. 
Questions? Speak with one of our experts? Contact Us. Proactive Investors: Emyria's Ultra-Pure CBD Capsule Outperforms TGA-Approved CBD Treatment in Pre-Clinical Animal TrialDrug Discovery World: Pharmacokinetic Study for Developing Kidney Disease and Injury Therapies |
